US OptionsDetailed Quotes
RIGL250117C18000
- 1.45
- 0.000.00%
15min DelayTrading Jan 17 16:00 ET
0.00High0.00Low
0.00Open1.45Pre Close0 Volume0 Open Interest18.00Strike Price0.00Turnover0.00%IV-8.34%PremiumJan 17, 2025Expiry Date3.22Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma14.63Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Rigel Pharmaceuticals Stock Discussion
21.+
and back to 20.+
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
WSJ· 08:36
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Thursday, 9th January at 8:05 am
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, ...
No comment yet